AAPL343.57+1.57 (+0.46%) ▲|ABBV285.36+1.96 (+0.69%) ▲|ABT104.89+0.21 (+0.20%) ▲|ACN229.63+4.71 (+2.09%) ▲|ADBE245.20-6.47 (-2.57%) ▼|AMAT409.29-20.72 (-4.82%) ▼|AMD528.75-33.48 (-5.95%) ▼|AMGN432.49-1.54 (-0.35%) ▼|AMT185.29+3.93 (+2.16%) ▲|AMZN250.00-4.76 (-1.87%) ▼|AVGO328.75-15.58 (-4.52%) ▼|AXP313.60-0.27 (-0.09%) ▼|BA190.04+1.31 (+0.69%) ▲|BAC51.23-0.48 (-0.92%) ▼|BKNG163.45-2.35 (-1.42%) ▼|BLK1,133.87+13.09 (+1.17%) ▲|BMY59.84-0.74 (-1.21%) ▼|BNY143.25+1.16 (+0.82%) ▲|BRK-B532.02+6.34 (+1.21%) ▲|C124.23+1.02 (+0.83%) ▲|CAT730.79-4.85 (-0.66%) ▼|CL94.08+1.41 (+1.52%) ▲|CMCSA21.90+0.13 (+0.60%) ▲|COF201.74+2.88 (+1.45%) ▲|COP146.51+4.78 (+3.37%) ▲|COST989.11+11.10 (+1.14%) ▲|CRM240.68-6.06 (-2.46%) ▼|CSCO107.39-2.46 (-2.24%) ▼|CVS92.37-0.21 (-0.23%) ▼|CVX224.97+5.65 (+2.58%) ▲|DE641.85-8.82 (-1.36%) ▼|DHR229.03-2.47 (-1.07%) ▼|DIS110.57-0.11 (-0.10%) ▼|DUK121.47+2.59 (+2.18%) ▲|EMR161.45-0.70 (-0.43%) ▼|FDX293.53-2.01 (-0.68%) ▼|GD344.15+7.12 (+2.11%) ▲|GE313.94+1.94 (+0.62%) ▲|GEV921.02-5.42 (-0.59%) ▼|GILD156.19-1.18 (-0.75%) ▼|GM83.96+0.30 (+0.36%) ▲|GOOG336.91-8.00 (-2.32%) ▼|GOOGL340.59-8.63 (-2.47%) ▼|GS880.60-10.69 (-1.20%) ▼|HD309.63+1.39 (+0.45%) ▲|HON211.41+0.91 (+0.43%) ▲|IBM232.14-1.98 (-0.85%) ▼|INTC89.85-5.52 (-5.79%) ▼|INTU325.15-5.02 (-1.52%) ▼|ISRG426.70-1.16 (-0.27%) ▼|JNJ255.60+2.32 (+0.92%) ▲|JPM339.72+4.19 (+1.25%) ▲|KO93.86+1.86 (+2.02%) ▲|LIN498.43+5.21 (+1.06%) ▲|LLY1,257.26+5.65 (+0.45%) ▲|LMT551.73+19.09 (+3.58%) ▲|LOW197.35+1.63 (+0.83%) ▲|LRCX263.94-13.52 (-4.87%) ▼|MA617.24+0.92 (+0.15%) ▲|MCD242.94+0.44 (+0.18%) ▲|MDLZ63.91+0.88 (+1.40%) ▲|MDT94.76-0.69 (-0.72%) ▼|META709.33-27.40 (-3.72%) ▼|MMM164.72-0.61 (-0.37%) ▼|MO75.10+1.26 (+1.71%) ▲|MRK145.93+0.74 (+0.51%) ▲|MS180.53-1.57 (-0.86%) ▼|MSFT529.05-10.39 (-1.93%) ▼|MU878.84-52.40 (-5.63%) ▼|NEE79.79+0.83 (+1.05%) ▲|NFLX70.53-2.08 (-2.86%) ▼|NKE37.13-0.02 (-0.04%) ▼|NOW141.95-6.62 (-4.46%) ▼|NVDA214.13-3.10 (-1.43%) ▼|ORCL128.22-6.25 (-4.65%) ▼|PEP131.49+3.11 (+2.42%) ▲|PFE29.57+0.13 (+0.44%) ▲|PG159.33+2.25 (+1.43%) ▲|PLTR186.03-14.47 (-7.22%) ▼|PM204.93+5.03 (+2.52%) ▲|QCOM172.11-6.29 (-3.53%) ▼|RTX193.92+6.97 (+3.73%) ▲|SBUX97.52+0.64 (+0.66%) ▲|SCHW91.96-2.20 (-2.34%) ▼|SO91.18+2.00 (+2.24%) ▲|SPG205.44+2.05 (+1.01%) ▲|T23.43-0.07 (-0.30%) ▼|TMO690.37-6.12 (-0.88%) ▼|TMUS159.10+2.07 (+1.32%) ▲|TSLA354.72-7.72 (-2.13%) ▼|TXN276.48-2.64 (-0.95%) ▼|UBER70.35-0.92 (-1.29%) ▼|UNH401.43-5.24 (-1.29%) ▼|UNP289.04+0.33 (+0.11%) ▲|UPS97.48-0.35 (-0.36%) ▼|USB58.73+1.34 (+2.33%) ▲|V402.61+2.86 (+0.72%) ▲|VZ44.79+0.39 (+0.88%) ▲|WFC83.87+1.12 (+1.35%) ▲|WMT118.81+0.94 (+0.80%) ▲|XOM178.98+4.30 (+2.46%) ▲|AAPL343.57+1.57 (+0.46%) ▲|ABBV285.36+1.96 (+0.69%) ▲|ABT104.89+0.21 (+0.20%) ▲|ACN229.63+4.71 (+2.09%) ▲|ADBE245.20-6.47 (-2.57%) ▼|AMAT409.29-20.72 (-4.82%) ▼|AMD528.75-33.48 (-5.95%) ▼|AMGN432.49-1.54 (-0.35%) ▼|AMT185.29+3.93 (+2.16%) ▲|AMZN250.00-4.76 (-1.87%) ▼|AVGO328.75-15.58 (-4.52%) ▼|AXP313.60-0.27 (-0.09%) ▼|BA190.04+1.31 (+0.69%) ▲|BAC51.23-0.48 (-0.92%) ▼|BKNG163.45-2.35 (-1.42%) ▼|BLK1,133.87+13.09 (+1.17%) ▲|BMY59.84-0.74 (-1.21%) ▼|BNY143.25+1.16 (+0.82%) ▲|BRK-B532.02+6.34 (+1.21%) ▲|C124.23+1.02 (+0.83%) ▲|CAT730.79-4.85 (-0.66%) ▼|CL94.08+1.41 (+1.52%) ▲|CMCSA21.90+0.13 (+0.60%) ▲|COF201.74+2.88 (+1.45%) ▲|COP146.51+4.78 (+3.37%) ▲|COST989.11+11.10 (+1.14%) ▲|CRM240.68-6.06 (-2.46%) ▼|CSCO107.39-2.46 (-2.24%) ▼|CVS92.37-0.21 (-0.23%) ▼|CVX224.97+5.65 (+2.58%) ▲|DE641.85-8.82 (-1.36%) ▼|DHR229.03-2.47 (-1.07%) ▼|DIS110.57-0.11 (-0.10%) ▼|DUK121.47+2.59 (+2.18%) ▲|EMR161.45-0.70 (-0.43%) ▼|FDX293.53-2.01 (-0.68%) ▼|GD344.15+7.12 (+2.11%) ▲|GE313.94+1.94 (+0.62%) ▲|GEV921.02-5.42 (-0.59%) ▼|GILD156.19-1.18 (-0.75%) ▼|GM83.96+0.30 (+0.36%) ▲|GOOG336.91-8.00 (-2.32%) ▼|GOOGL340.59-8.63 (-2.47%) ▼|GS880.60-10.69 (-1.20%) ▼|HD309.63+1.39 (+0.45%) ▲|HON211.41+0.91 (+0.43%) ▲|IBM232.14-1.98 (-0.85%) ▼|INTC89.85-5.52 (-5.79%) ▼|INTU325.15-5.02 (-1.52%) ▼|ISRG426.70-1.16 (-0.27%) ▼|JNJ255.60+2.32 (+0.92%) ▲|JPM339.72+4.19 (+1.25%) ▲|KO93.86+1.86 (+2.02%) ▲|LIN498.43+5.21 (+1.06%) ▲|LLY1,257.26+5.65 (+0.45%) ▲|LMT551.73+19.09 (+3.58%) ▲|LOW197.35+1.63 (+0.83%) ▲|LRCX263.94-13.52 (-4.87%) ▼|MA617.24+0.92 (+0.15%) ▲|MCD242.94+0.44 (+0.18%) ▲|MDLZ63.91+0.88 (+1.40%) ▲|MDT94.76-0.69 (-0.72%) ▼|META709.33-27.40 (-3.72%) ▼|MMM164.72-0.61 (-0.37%) ▼|MO75.10+1.26 (+1.71%) ▲|MRK145.93+0.74 (+0.51%) ▲|MS180.53-1.57 (-0.86%) ▼|MSFT529.05-10.39 (-1.93%) ▼|MU878.84-52.40 (-5.63%) ▼|NEE79.79+0.83 (+1.05%) ▲|NFLX70.53-2.08 (-2.86%) ▼|NKE37.13-0.02 (-0.04%) ▼|NOW141.95-6.62 (-4.46%) ▼|NVDA214.13-3.10 (-1.43%) ▼|ORCL128.22-6.25 (-4.65%) ▼|PEP131.49+3.11 (+2.42%) ▲|PFE29.57+0.13 (+0.44%) ▲|PG159.33+2.25 (+1.43%) ▲|PLTR186.03-14.47 (-7.22%) ▼|PM204.93+5.03 (+2.52%) ▲|QCOM172.11-6.29 (-3.53%) ▼|RTX193.92+6.97 (+3.73%) ▲|SBUX97.52+0.64 (+0.66%) ▲|SCHW91.96-2.20 (-2.34%) ▼|SO91.18+2.00 (+2.24%) ▲|SPG205.44+2.05 (+1.01%) ▲|T23.43-0.07 (-0.30%) ▼|TMO690.37-6.12 (-0.88%) ▼|TMUS159.10+2.07 (+1.32%) ▲|TSLA354.72-7.72 (-2.13%) ▼|TXN276.48-2.64 (-0.95%) ▼|UBER70.35-0.92 (-1.29%) ▼|UNH401.43-5.24 (-1.29%) ▼|UNP289.04+0.33 (+0.11%) ▲|UPS97.48-0.35 (-0.36%) ▼|USB58.73+1.34 (+2.33%) ▲|V402.61+2.86 (+0.72%) ▲|VZ44.79+0.39 (+0.88%) ▲|WFC83.87+1.12 (+1.35%) ▲|WMT118.81+0.94 (+0.80%) ▲|XOM178.98+4.30 (+2.46%) ▲|
22.9 C
New York
Friday, October 16, 2026

Tag: doses

Eisai Deepens Its Oncology Evidence Base at ESMO Congress 2026

Findings from the Phase 3 LITESPARK-011 and LITESPARK-012 studies reflect continued research into LENVIMA® (lenvatinib)-based combination regimens for patients with advanced renal cell carcinomaExploratory...

Pompe Disease Market Set for Expansion During the Forecast Period (2026-2036) as Growth is Fueled by Next-Generation ERTs, Newborn Screening, and Pipeline Innovation |...

The Pompe disease market is estimated to change significantly during the forecast period (2026–2036), owing to the launch of novel therapies including MZE001 (S-606001;...

Interim Real-World Results Show At-Home Subcutaneous Furosemide Can Effectively Treat Worsening Heart Failure in Patients at Imminent Risk for Hospital Admission

Gator SCALES-WHF, an investigator-sponsored study at the University of Florida, shows effective decongestion of patients at imminent risk for hospital admission with minimal user,...

Accord BioPharma Launches FILKRI™ (filgrastim-laha); Now Offers Both Long- and Short-Acting G-CSF Options

FILKRI is available with a permanent Q-code, standardizing the billing and reimbursement process across all sites of care.RALEIGH, N.C., Oct. 12, 2026 /PRNewswire/ -- Accord...

Racura Oncology Cleared to Escalate RC220 to 100 mg/m2 in Phase 1 HARNESS-1 Trial in EGFR-Mutant Non-Small Cell Lung Cancer

The HARNESS-1 Safety Review Committee identified no dose-limiting toxicities or treatment-related safety concerns in either Cohort 1 patient during the safety observation period and...

Sebela Pharmaceuticals to Present Positive Phase 3 Tegoprazan Data in Non-Erosive Reflux Disease (NERD) at the American College of Gastroenterology (ACG) 2026 Meeting

Key Highlights:Tegoprazan is the first and only P-CAB reported to demonstrate clinical improvement in both hallmark symptoms of NERD, heartburn and regurgitation, in a...

Drug Delivery Devices Market to Reach US$ 698.2 Bn by 2031, Growing at 7.4% CAGR as Smart and Wearable Devices Expand: New Report by...

SHERIDAN, Wyo., Oct. 6, 2026 /PRNewswire/ -- The global drug delivery devices market is projected to grow from USD 488.6 billion in 2026 to USD...

Drug Delivery Devices Market to Reach US$ 698.2 Bn by 2031, Growing at 7.4% CAGR as Smart and Wearable Devices Expand: New Report by...

SHERIDAN, Wyo., Oct. 6, 2026 /PRNewswire/ -- The global drug delivery devices market is projected to grow from USD 488.6 billion in 2026 to USD...

HelloNation Article Featuring Eye Care Experts, Dr. R. Krishna Sanka and Dr. Singh, Examines Whether Reducing Glaucoma Eye Drops Can Improve Quality of Life

The article explains how newer glaucoma treatment options may help simplify long-term glaucoma care for some patients.KENOSHA, Wis., Oct. 6, 2026 /PRNewswire/ -- Can...

Beactica Therapeutics selects BEA-28 as a preclinical candidate, a first-in-class TEAD degrader for biomarker-selected cancers

UPPSALA, Sweden, Oct. 6, 2026 /PRNewswire/ -- Beactica Therapeutics AB, a Swedish precision medicine company, today announced the selection of BEA-28 as a preclinical...

UK Government Strengthens Vaccine Partnership with CSL Seqirus, Introducing World-First Flu vaccine (aTIVc) and Extending Health Security Pandemic Agreement

The new CSL Seqirus-developed vaccine will be introduced to the annual influenza vaccination programme from next year (2027/28).Its introduction marks a significant advance in...

Lilly breaks ground in Houston, one of ten U.S. manufacturing sites announced since 2020

New facility will manufacture active pharmaceutical ingredients for medicines like Foundayo (orforglipron), strengthening domestic supply chainSite will employ more than 600 people in high-wage...

Two Hyundai Hope on Wheels Handprint Ceremonies, two brave kids, one mission to end childhood cancer

The Hyundai Hope on Wheels national tour stopped in Eastern Ontario, with Handprint Ceremonies at Kingston General Hospital and a local dealership alongside CHEO...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDoses